All‐cause mortality · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in mortality compared with heparin (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in recurrent VTE compared with heparin (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in major bleeding compared with heparin (low certainty).
1 finding from 1 review
Minor bleeding · patients with cancer with venous thromboembolism
Fondaparinux showed no clear difference in minor bleeding compared with heparin (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postphlebitic syndrome ‐ not reported · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality ‐ not reported · People with cancer with perioperative thromboprophylaxis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total VTE · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in any VTE compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in major Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in minor Bleeding compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Pulmonary embolism · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in any Pulmonary embolism compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Postoperative drain volume · People with cancer with perioperative thromboprophylaxis
1 finding from 1 review